13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04035889
(ClinicalTrials.gov)
September 23, 201925/7/2019Melatonin for Sleep in MSA Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)Multiple SclerosisDietary Supplement: Melatonin;Dietary Supplement: PlaceboUniversity of California, San FranciscoNULLCompleted20 Years70 YearsAll30N/AUnited States
2NCT03498131
(ClinicalTrials.gov)
May 9, 20186/4/2018Melatonin in Patients With Multiple Sclerosis (MS).Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)Relapsing Remitting Multiple SclerosisDrug: 3 mg Melatonin;Drug: 5 mg MelatoninProvidence Health & ServicesNULLActive, not recruiting18 Years65 YearsAll30Early Phase 1United States
3EUCTR2012-004183-21-GB
(EUCTR)
25/01/201314/12/2012Melatonin for Nocturia in patients with Multiple SclerosisA randomized, double blind, placebo controlled, cross over trial of Melatonin for the treatment of nocturia in adults with progressive multiple sclerosis, with an open label, single-arm extension study - Melatonin for Nocturia in MS Nocturia; Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Circadin
Product Name: Circadin
Product Code: N/A
INN or Proposed INN: Circadin ( INN= Melatonin)
North Bristol NHS TrustNULLNot Recruiting Female: yes
Male: yes
80 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
4NCT02463318
(ClinicalTrials.gov)
September 20122/6/2015The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy SubjectsMultiple Sclerosis;Oxidative StressDrug: Melatonin;Other: Hydrogen peroxideTehran University of Medical SciencesNULLCompleted20 Years40 YearsFemale34N/AIran, Islamic Republic of
5NCT01718678
(ClinicalTrials.gov)
May 201228/10/2012Effect of Melatonin on Multiple Sclerosis Related FatigueStudy of Melatonin in Treatment of Fatigue in Multiple SclerosisFatigueDrug: Melatonin;Drug: PlaceboIsfahan University of Medical SciencesNULLCompleted18 Years55 YearsBoth44Phase 2Iran, Islamic Republic of
6NCT01279876
(ClinicalTrials.gov)
October 201018/1/2011Melatonin in Relapsing-Remitting Multiple Sclerosis PatientsEffects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis PatientsMultiple Sclerosis, Relapsing-RemittingDrug: MelatoninTehran University of Medical SciencesNULLCompleted20 Years45 YearsBoth25Phase 2Iran, Islamic Republic of